Search
Hexaminolevulinate
go.drugbank.com/drugs/DB06261ApprovedInvestigationalIn solution form it is instilled intravesically for use with photodynamic blue light cystoscopy as an adjunct to white light cystoscopy. On May 28, 2010, the U.S. … Food and Drug Administration (FDA) granted approval for hexaminolevulinate hydrochloride (Cysview for Intravesical Solution, Photocure ASA), as an optical imaging agent for use in combination with the
Monopotassium phosphate
go.drugbank.com/drugs/DB09413ApprovedInvestigationalVet approvedIt is a source of phosphorus and potassium as well as a buffering agent. It can be used in fertilizer mixtures to reduce escape of ammonia by keeping pH low.
Mixtures: Clinimix 3 % G-E - Infusionsbeutel, Clinimix 5 % G-E - InfusionsbeutelCER-001
go.drugbank.com/drugs/DB18538Investigational[L48290] It is under investigation for the treatment of lecithin-cholesterol acyltransferase (LCAT) deficiencies. … CER-001 is a negatively charged lipoprotein particle comprising human recombinant apolipoprotein A-I and two phospholipids: sphingomyelin and dipalmitoylphosphatidylglycerol.
Sutimlimab
go.drugbank.com/drugs/DB14996ApprovedInvestigationalreferred to as "cold agglutinin". … [A245159] Pharmacologic strategies have included the targeting of B-cells with agents like [rituximab], as well as targeting of the complement system with drugs like [eculizumab], an anti-C5 mAb, and [
Pacritinib
go.drugbank.com/drugs/DB11697ApprovedInvestigationalhas made it a desirable therapeutic target in MF treatment. … Pacritinib is an inhibitor of both wild-type and mutant (V617F) JAK2, as well as FMS-like tyrosine kinase 3 (FLT3), which was granted accelerated approval by the FDA in February 2022 for the treatment
Milnacipran
go.drugbank.com/drugs/DB04896ApprovedInvestigationalFurthermore, in 2009 the US FDA approved milnacipran for the additional indication of treating fibromyalgia [F3925], although other regional regulatory authorities like the EMA, among others, have not yet … -1 (BACE-1), which has investigationally been associated with β-amyloid plaque formation - making the agent a possible course of treatment for Alzheimer's disease [A175957].
Tazemetostat
go.drugbank.com/drugs/DB12887ApprovedInvestigational[L11476] Tazemetostat was first named in literature as EPZ-6438.[A190363] Tazemetaostat was granted FDA approval on 23 January 2020.[L11476]
Dihydroergocornine
go.drugbank.com/drugs/DB11273Approved[T190] It is found as one of the components in the ergoloid mesylate mixture. To know more about this mixture please refer to [DB01049] … [A32962] It is an artificial derivative of the crude extract of ergot and later purified, ergocornine.
Oxymetazoline
go.drugbank.com/drugs/DB00935ApprovedInvestigational[L15062] As an effective decongestant, oxymetazoline is available in over-the-counter intranasal sprays used to relieve nasal and sinus congestion caused by a wide variety of conditions, such as common … [L15057] In July 2020, the FDA approved the use of an ophthalmic formulation of oxymetazoline (Upneeq) in adults with acquired blepharoptosis, or ptosis, making it the first FDA-approved medical treatment
Categories: Sympathomimetics Used as DecongestantsSynonyms: 6-t-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenolExagamglogene autotemcel
go.drugbank.com/drugs/DB15572ApprovedInvestigationalIt was approved by the FDA in December 2023 for the treatment of patients with SCD with recurrent vaso-occlusive crises. … [L49231] It is the first CRISPR-based gene editing therapy to be approved in the United States.